Hammouda Amina, Souilah Souad, Ferhat-Hamida Meriem Yasmine, Amir Zine Charaf, Bouguerra Souhila Aouichat, Hariti Ghania
Laboratoire de biologie et physiologie, Équipe de physiopathologie cellulaire et moléculaire, Faculté des sciences biologiques, Université des sciences et de la technologie Houari-Boumediene, Alger, Algérie.
Service de pneumologie, CHU Bab-El-Oued, Alger, Algérie.
Ann Biol Clin (Paris). 2021 Feb 1;79(1):41-48. doi: 10.1684/abc.2021.1623.
During primary hemostasis the platelets aggregate to form the platelet thrombus. ADP and thrombin generated by coagulation are the main agonists in platelet aggregation. In a previous study we were able to show that patients with lung cancer had hypercoagulability, hyperfibrinogemia (≥ 6.22 g/L) was predictive of thromboembolic disease at the start of diagnosis before any therapy. In this study, we studied platelet aggregation in these patients in order to demonstrate whether they have hyperaggregability associated with the hypercoagulability demonstrated previously, and this by evaluating abnormalities in primary hemostasis (platelet count and platelet aggregation). One hundred and one patients diagnosed before any therapy and 72 blood donors were included. Agonists used for platelet aggregation are collagen and adenosine diphosphate at low concentrations. Hyperaggregability is observed when blood platelets are stimulated by ADP at different concentrations (p ≤ 0.01). This hyperaggregability is influenced by the histological type and not the development of the cancer, the age of the subjects and the platelet count, it is independent of hyperfibrinogemia and the occurrence of thromboembolic disease. However, an increase in the platelet level is found in patients with hyperfibrinogemia. Patients with lung cancer present platelet activation observed by aggregometry in response to ADP; which is not influenced by hyperfibrinogemia during cancer.
在初级止血过程中，血小板聚集形成血小板血栓。凝血产生的二磷酸腺苷（ADP）和凝血酶是血小板聚集的主要激动剂。在先前的一项研究中，我们发现肺癌患者具有高凝性，高纤维蛋白原血症（≥6.22g/L）在诊断开始且未进行任何治疗之前可预测血栓栓塞性疾病。在本研究中，我们对这些患者的血小板聚集情况进行了研究，以证明他们是否存在与先前证明的高凝性相关的高聚集性，方法是评估初级止血的异常情况（血小板计数和血小板聚集）。纳入了101例在未进行任何治疗前被诊断的患者和72名献血者。用于血小板聚集的激动剂是胶原蛋白和低浓度的二磷酸腺苷。当血小板受到不同浓度的ADP刺激时，可观察到高聚集性（p≤0.01）。这种高聚集性受组织学类型影响，而不受癌症进展、受试者年龄和血小板计数影响，它独立于高纤维蛋白原血症和血栓栓塞性疾病的发生。然而，高纤维蛋白原血症患者的血小板水平会升高。肺癌患者通过血小板聚集测定法可观察到对ADP有血小板激活反应；这在癌症期间不受高纤维蛋白原血症影响。
